Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALKS 1140 in Healthy Adults
NCT05019105Phase 1Terminated
- Sponsor
- Alkermes
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in neurodegenerative diseases and neurological disorders comparing Placebo with ALKS 1140 (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events up to 28 days, Change in Columbia-Suicide Severity Rating Scale up to 28 days and 1 more. Started Oct 2021; status: terminated.
02
Drugs
RDN-929
03
Conditions
neurodegenerative diseasesneurological disorders
Beyond the preview
Go deeper on NCT05019105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019105.